35 Days
المصدر:
صحة
صحة
جاهز للتشغيل
جاهز للتشغيل
Researchers from the University of Cambridge and DIOSynVax announced the successful completion of the first early human trial of a candidate vaccine against a group of coronaviruses. The vaccine utilizes a needle-free, skin-delivery technique and is designed through computational simulation. The trial showed that the vaccine, which targets the Sarbecovirus family and aims to identify common features across viruses, is safe and elicited a modest immune response against variants such as Delta and Omicron. This technology represents a step toward developing broad-spectrum vaccines against constantly evolving viruses, with the potential to be adapted for other diseases like influenza and hemorrhagic viruses.
تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي
comments.heading